RS56452B1 - Fenoksietil piperidin jedinjenja - Google Patents

Fenoksietil piperidin jedinjenja

Info

Publication number
RS56452B1
RS56452B1 RS20171039A RSP20171039A RS56452B1 RS 56452 B1 RS56452 B1 RS 56452B1 RS 20171039 A RS20171039 A RS 20171039A RS P20171039 A RSP20171039 A RS P20171039A RS 56452 B1 RS56452 B1 RS 56452B1
Authority
RS
Serbia
Prior art keywords
compound
mmol
pharmaceutically acceptable
methyl
acceptable salt
Prior art date
Application number
RS20171039A
Other languages
English (en)
Serbian (sr)
Inventor
Matthew Allen Schiffler
Jeremy Schulenburg York
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of RS56452B1 publication Critical patent/RS56452B1/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/45Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RS20171039A 2012-06-29 2013-06-20 Fenoksietil piperidin jedinjenja RS56452B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261665951P 2012-06-29 2012-06-29
US201361779099P 2013-03-13 2013-03-13
EP13734248.1A EP2867207B1 (en) 2012-06-29 2013-06-20 Phenoxyethyl piperidine compounds
PCT/US2013/046684 WO2014004229A1 (en) 2012-06-29 2013-06-20 Phenoxyethyl piperidine compounds

Publications (1)

Publication Number Publication Date
RS56452B1 true RS56452B1 (sr) 2018-01-31

Family

ID=48746666

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20171039A RS56452B1 (sr) 2012-06-29 2013-06-20 Fenoksietil piperidin jedinjenja

Country Status (42)

Country Link
US (2) US8962659B2 (enExample)
EP (1) EP2867207B1 (enExample)
JP (1) JP6127136B2 (enExample)
KR (1) KR101653476B1 (enExample)
CN (1) CN104411684B (enExample)
AP (1) AP2014008164A0 (enExample)
AR (1) AR091429A1 (enExample)
AU (1) AU2013280875B2 (enExample)
BR (1) BR112014031616B1 (enExample)
CA (1) CA2875569C (enExample)
CL (1) CL2014003535A1 (enExample)
CO (1) CO7151507A2 (enExample)
CR (1) CR20140553A (enExample)
CY (1) CY1119425T1 (enExample)
DK (1) DK2867207T3 (enExample)
DO (1) DOP2014000287A (enExample)
EA (1) EA024392B1 (enExample)
EC (1) ECSP14033267A (enExample)
ES (1) ES2644812T3 (enExample)
GT (1) GT201400288A (enExample)
HR (1) HRP20171515T1 (enExample)
HU (1) HUE034425T2 (enExample)
IL (1) IL236219A (enExample)
JO (1) JO3296B1 (enExample)
LT (1) LT2867207T (enExample)
MA (1) MA37686B1 (enExample)
ME (1) ME02840B (enExample)
MX (1) MX345324B (enExample)
MY (1) MY173878A (enExample)
NZ (1) NZ701933A (enExample)
PE (1) PE20150182A1 (enExample)
PH (1) PH12015500009B1 (enExample)
PL (1) PL2867207T3 (enExample)
PT (1) PT2867207T (enExample)
RS (1) RS56452B1 (enExample)
SG (1) SG11201408641UA (enExample)
SI (1) SI2867207T1 (enExample)
TN (1) TN2014000501A1 (enExample)
TW (1) TWI599561B (enExample)
UA (1) UA114325C2 (enExample)
WO (1) WO2014004229A1 (enExample)
ZA (1) ZA201408632B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR091429A1 (es) * 2012-06-29 2015-02-04 Lilly Co Eli Compuestos de fenoxietil piperidina
TWI636046B (zh) * 2013-05-17 2018-09-21 美國禮來大藥廠 苯氧基乙基二氫-1h-異喹啉化合物
PL3083562T3 (pl) * 2013-12-17 2018-02-28 Eli Lilly & Company Pochodne fenoksyetylowych cyklicznych amin i ich aktywność jako modulatorów receptora EP4
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
SG11201908660RA (en) 2017-05-18 2019-10-30 Idorsia Pharmaceuticals Ltd N-substituted indole derivatives
PL3625228T3 (pl) 2017-05-18 2021-12-20 Idorsia Pharmaceuticals Ltd Pochodne pirymidyny jako modulatory receptora pge2
IL270623B2 (en) 2017-05-18 2023-03-01 Idorsia Pharmaceuticals Ltd History of phenyl as pge2 receptor modulators
AR111807A1 (es) 2017-05-18 2019-08-21 Idorsia Pharmaceuticals Ltd Derivados de benzofurano y benzotiofeno como moduladores del receptor pge2
JP7253500B2 (ja) 2017-05-18 2023-04-06 イドーシア ファーマシューティカルズ リミテッド ピリミジン誘導体
CA3126484A1 (en) * 2019-01-22 2020-07-30 Keythera (Suzhou) Pharmaceuticals Co. Ltd. Compound for inhibiting pge2/ep4 signaling transduction inhibiting, preparation method therefor, and medical uses thereof
US20230390303A1 (en) 2020-11-13 2023-12-07 Ono Pharmaceutical Co., Ltd. Cancer treatment by combination of ep4 antagonist and immune checkpoint inhibitor
GB202211232D0 (en) 2022-08-02 2022-09-14 Heptares Therapeutics Ltd Prostaglandin EP4 receptor agonist compounds

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2500157C2 (de) 1975-01-03 1983-09-15 Hoechst Ag, 6230 Frankfurt N-Acyl-4-(2-aminoäthyl)-benzoesäuren, deren Salze und Ester, Verfahren zu deren Herstellung und deren Verwendung
JP2005531516A (ja) * 2002-03-18 2005-10-20 ファイザー・プロダクツ・インク 選択的ep4受容体アゴニストによる治療方法
MXPA05007341A (es) * 2003-01-10 2005-09-30 Hoffmann La Roche Derivados de 2-piperidona como agonistas de prostaglandina.
MXPA06002551A (es) * 2003-09-03 2006-06-20 Pfizer Compuestos de aril o heteroaril amida.
US20050105732A1 (en) * 2003-11-17 2005-05-19 Hutchings George T. Systems and methods for delivering pre-encrypted content to a subscriber terminal
EA200601847A1 (ru) 2004-05-04 2007-04-27 Пфайзер Инк. Замещённые метиларил- или гетероариламидные соединения
AP2006003769A0 (en) 2004-05-04 2006-10-31 Pfizer Ortho substituted aryl or heteroaryl amide compounds
US7592364B2 (en) * 2006-02-28 2009-09-22 Allergan, Inc. Substituted gamma lactams as therapeutic agents
US7968578B2 (en) 2006-04-24 2011-06-28 Merck Frosst Canada Ltd. Indole amide derivatives as EP4 receptor antagonists
AU2007260529B2 (en) 2006-06-12 2012-04-19 Merck Canada Inc. Indoline amide derivatives as EP4 receptor ligands
WO2008092860A1 (en) * 2007-01-30 2008-08-07 Janssen Pharmaceutica N.V. Bicyclic derivatives as ep4 agonists
RU2479576C9 (ru) 2008-05-14 2014-03-10 Астеллас Фарма Инк. Амидное соединение
US8404736B2 (en) 2008-08-14 2013-03-26 Beta Pharma Canada Inc. Heterocyclic amide derivatives as EP4 receptor antagonists
KR101780666B1 (ko) * 2010-02-22 2017-09-21 에스크엣 인크. Il-23 매개 질환의 치료에서 ep4 수용체 길항제의 용도
EP2619182B1 (en) * 2010-09-21 2016-11-09 Eisai R&D Management Co., Ltd. Pharmaceutical composition
ES2564353T3 (es) 2011-07-04 2016-03-22 Rottapharm Biotech S.R.L. Derivados de aminas cíclicas como agonistas de los receptores EP4
BR112014000087B1 (pt) * 2011-07-04 2021-08-17 Rottapharm Biotech S.R.L. Derivados de amina cíclica como antagonistas do receptor ep4
AR091429A1 (es) * 2012-06-29 2015-02-04 Lilly Co Eli Compuestos de fenoxietil piperidina

Also Published As

Publication number Publication date
AR091429A1 (es) 2015-02-04
KR101653476B1 (ko) 2016-09-01
GT201400288A (es) 2015-08-27
EP2867207A1 (en) 2015-05-06
SI2867207T1 (sl) 2017-10-30
US9402838B2 (en) 2016-08-02
PE20150182A1 (es) 2015-02-13
SG11201408641UA (en) 2015-01-29
CA2875569C (en) 2016-04-19
CN104411684A (zh) 2015-03-11
ECSP14033267A (es) 2015-09-30
JO3296B1 (ar) 2018-09-16
US20140005226A1 (en) 2014-01-02
EA024392B1 (ru) 2016-09-30
HK1203937A1 (en) 2015-11-06
TWI599561B (zh) 2017-09-21
BR112014031616A2 (pt) 2017-06-27
MA37686B1 (fr) 2017-04-28
TW201412717A (zh) 2014-04-01
IL236219A (en) 2017-12-31
HRP20171515T1 (hr) 2017-11-17
DK2867207T3 (en) 2017-09-11
HUE034425T2 (en) 2018-02-28
EP2867207B1 (en) 2017-08-09
ZA201408632B (en) 2017-06-28
EA201492255A1 (ru) 2015-03-31
KR20150013893A (ko) 2015-02-05
JP2015522018A (ja) 2015-08-03
PH12015500009B1 (en) 2020-10-09
BR112014031616B1 (pt) 2022-06-21
PL2867207T3 (pl) 2018-01-31
US8962659B2 (en) 2015-02-24
MX2014015953A (es) 2015-07-17
CR20140553A (es) 2015-02-04
AU2013280875A1 (en) 2014-12-04
MX345324B (es) 2017-01-25
IL236219A0 (en) 2015-02-01
MY173878A (en) 2020-02-26
UA114325C2 (uk) 2017-05-25
WO2014004229A1 (en) 2014-01-03
CL2014003535A1 (es) 2015-05-08
LT2867207T (lt) 2017-10-10
NZ701933A (en) 2017-01-27
DOP2014000287A (es) 2015-01-31
PH12015500009A1 (en) 2015-03-02
AU2013280875B2 (en) 2015-09-24
ES2644812T3 (es) 2017-11-30
CA2875569A1 (en) 2014-01-03
CN104411684B (zh) 2016-08-24
US20150126555A1 (en) 2015-05-07
CO7151507A2 (es) 2014-12-29
MA37686A1 (fr) 2016-09-30
TN2014000501A1 (en) 2016-03-30
CY1119425T1 (el) 2018-03-07
PT2867207T (pt) 2017-11-01
AP2014008164A0 (en) 2014-12-31
ME02840B (me) 2018-01-20
JP6127136B2 (ja) 2017-05-10

Similar Documents

Publication Publication Date Title
RS56452B1 (sr) Fenoksietil piperidin jedinjenja
JP6212644B2 (ja) フェノキシエチル環状アミン誘導体およびep4受容体モジュレーターとしてのその活性
US9000043B2 (en) Phenoxyethoxy compounds
JP6148400B2 (ja) フェノキシエチルジヒドロ−1h−イソキノリン化合物
RS58594B1 (sr) Jedinjenja dimetilbenzoeve kiseline
HUE032398T2 (en) Dimethylbenzoic acid compounds for treating inflammatory conditions
AU2014265762B2 (en) Phenoxyethyl dihydro-1H-isoquinoline compounds
HK1203937B (en) Phenoxyethyl piperidine compounds